Pharmaceutical companies by P/E ratio
Share price divided by the last twelve months' earnings per share: how many years of today's profit the price pays for. A company making a loss has none.
Edgewise Therapeutics has the lowest figure of the 33 pharmaceutical companies ranked by P/E ratio, at 4.9, followed by Alnylam Pharmaceuticals (7.7) and Novo Nordisk (10.0). Figures as of 18 Nov 2026, 16:47 UTC, from Yahoo Finance quotes.
Key facts
- Companies ranked
- 33
- Lowest
- Edgewise Therapeutics4.9
- Median
- 40.3
- Combined market value
- SGD 6.56T
- Countries
- 10
- Not ranked
- 28no P/E ratio on file
Market values as of .
All countries▾
All sectors▾
Pharmaceuticals▾
| # | Company | P/E ↑ | Market cap | Price | Today | 1 year | Price, 30 days | Country |
|---|---|---|---|---|---|---|---|---|
| 1 | Edgewise TherapeuticsEWTX · Health Care | 4.9 | SGD 5.8B | SGD 53.14 | 2.00% down | 88% up | ||
| 2 | Alnylam PharmaceuticalsALNY · Health Care | 7.7 | SGD 26.2B | SGD 195.55 | 3.12% down | 66% down | ||
| 3 | Novo NordiskNVO · Health Care | 10.0 | SGD 224.8B | SGD 51.00 | 2.85% down | 17% down | ||
| 4 | GrifolsGRFS · Health Care | 10.3 | SGD 7.5B | SGD 10.98 | 1.33% down | 1% up | ||
| 5 | Bristol-Myers SquibbBMY · Health Care | 13.4 | SGD 158.7B | SGD 77.66 | 1.86% down | 34% up | ||
| 6 | ZoetisZTS · Health Care | 14.3 | SGD 44B | SGD 108.30 | 0.58% up | 29% down | ||
| 7 | GSKGSK · Health Care | 17.0 | SGD 126.1B | SGD 62.93 | 0.91% down | 6% up | ||
| 8 | Ascendis PharmaASND · Health Care | 17.8 | SGD 22.9B | SGD 349.62 | 0.04% down | 28% up | ||
| 9 | Regeneron PharmaceuticalsREGN · Health Care | 21.1 | SGD 127.6B | SGD 1,233.49 | 0.15% down | 36% up | ||
| 10 | United TherapeuticsUTHR · Health Care | 21.8 | SGD 31.8B | SGD 746.31 | 0.94% down | 23% up | ||
| 11 | SanofiSNY · Health Care | 23.5 | SGD 146.5B | SGD 61.03 | 0.45% down | 4% down | ||
| 12 | AstraZenecaAZN · Health Care | 25.4 | SGD 358.7B | SGD 231.26 | 1.63% down | 2% up | ||
| 13 | Protagonist TherapeuticsPTGX · Health Care | 26.5 | SGD 10.6B | SGD 161.75 | 0.59% up | 46% up | ||
| 14 | NovartisNVS · Health Care | 29.8 | SGD 379.8B | SGD 201.10 | 2.02% down | 25% up | ||
| 15 | Vertex PharmaceuticalsVRTX · Health Care | 34.4 | SGD 175B | SGD 690.38 | 0.20% up | 27% up | ||
| 16 | Abbott LaboratoriesABT · Health Care | 39.2 | SGD 234.4B | SGD 135.35 | 0.22% up | 17% down | ||
| 17 | PfizerPFE · Health Care | 40.3 | SGD 207.2B | SGD 36.35 | 1.00% down | 14% up | ||
| 18 | Dr. Reddy's LaboratoriesRDY · Health Care | 41.6 | SGD 16.1B | SGD 19.33 | 1.32% up | 5% up | ||
| 19 | Johnson & JohnsonJNJ · Health Care | 41.8 | SGD 856.2B | SGD 355.67 | 1.05% down | 38% up | ||
| 20 | GenmabGMAB · Health Care | 43.8 | SGD 40.7B | SGD 66.04 | 1.46% down | 70% up | ||
| 21 | Eli LillyLLY · Health Care | 45.0 | SGD 1.59T | SGD 1,788.44 | 2.04% down | 35% up | ||
| 22 | Royalty PharmaRPRX · Health Care | 45.0 | SGD 51.1B | SGD 88.81 | 0.26% up | 78% up | ||
| 23 | AbbVieABBV · Health Care | 49.7 | SGD 659.2B | SGD 372.93 | 1.26% down | 26% up | ||
| 24 | Corcept TherapeuticsCORT · Health Care | 51.2 | SGD 9.6B | SGD 87.77 | 2.88% down | 8% down | ||
| 25 | BeOne MedicinesONC · Health Care | 51.7 | SGD 59.4B | SGD 519.86 | 2.47% down | 17% up | ||
| 26 | Amneal PharmaceuticalsAMRX · Health Care | 53.9 | SGD 9.7B | SGD 27.80 | 2.06% up | 83% up | ||
| 27 | Jazz PharmaceuticalsJAZZ · Health Care | 72.2 | SGD 20.2B | SGD 314.87 | 1.42% up | 37% up | ||
| 28 | Kiniksa Pharmaceuticals InternationalKNSA · Health Care | 72.7 | SGD 9.7B | SGD 123.80 | 0.92% up | 126% up | ||
| 29 | TG TherapeuticsTGTX · Health Care | 97.4 | SGD 12.7B | SGD 84.20 | 4.10% up | 107% up | ||
| 30 | Teva Pharmaceutical IndustriesTEVA · Health Care | 98.3 | SGD 63.6B | SGD 54.51 | 0.84% down | 74% up | ||
| 31 | Ligand PharmaceuticalsLGND · Health Care | 121 | SGD 7.7B | SGD 387.13 | 2.16% up | 43% up | ||
| 32 | Merck & CoMRK · Health Care | 141 | SGD 444B | SGD 180.10 | 2.60% down | 51% up | ||
| 33 | Takeda PharmaceuticalTAK · Health Care | 305 | SGD 88.1B | SGD 27.57 | 1.22% down | 54% up |
Sources: share prices and market values from Yahoo Finance; sector, country and category from each company's SEC registration.
Market value is share price × shares outstanding, from Yahoo Finance; prices may be delayed 15 minutes or more and the ranking refreshes about every 20 minutes. The list covers companies with shares listed in the US, which includes foreign companies listed through ADRs but not ones listed only abroad. Sector, category and country come from each company's SEC registration. Sums are converted from US dollars at today's exchange rate (1 USD = 1.2898 SGD). 28 companies have no P/E ratio on file and are not ranked here.
Questions and answers
Which pharmaceutical companies have the lowest P/E ratio?
Edgewise Therapeutics (4.9), Alnylam Pharmaceuticals (7.7) and Novo Nordisk (10.0) have the lowest P/E ratio of the 33 pharmaceutical companies ranked here as of 18 Nov 2026, 16:47 UTC.
How many pharmaceutical companies are in this ranking?
33 are ranked by P/E ratio. 28 more have no P/E ratio on file and are left out rather than ranked at zero.
What are these pharmaceutical companies worth together?
The 33 pharmaceutical companies ranked by P/E ratio have a combined market value of SGD 6.56T as of 18 Nov 2026, 16:47 UTC.
What does ranking by P/E ratio measure?
Share price divided by the last twelve months' earnings per share: how many years of today's profit the price pays for. A company making a loss has none.
Learn how this ranking works
All markets guides →- P/E ratio explained: what a high or low figure means
The price-to-earnings (P/E) ratio is a share's price divided by its earnings per share. A stock at $100 earning $5 a share has a P/E of 20: buyers pay $20 for each dollar of yearly profit. A high P/E usually means the market expects profit to grow; a low one can mean doubt, not a bargain.
- PEG ratio: P/E adjusted for growth, and its limits
The PEG ratio is a stock's P/E divided by its expected yearly earnings growth in percent. A P/E of 20 with 10% expected growth gives a PEG of 2; with 20% growth, a PEG of 1. A PEG near 1 is the traditional rough mark of a fair price, but the growth figure is a forecast and often wrong.
- How an ETF's size is measured: AUM, NAV and creation units
An ETF's size is usually measured by its assets under management (AUM), the fund's net assets: everything it holds minus what it owes. That equals net asset value per share times shares outstanding. AUM grows when the holdings rise in value and when large institutions create new shares, and shrinks when they redeem them.
Cite this page
Funkfolio, “Pharmaceutical companies by P/E ratio”, data as of 18 November 2026. https://funkfolio.com/companies/category/pharmaceuticals?by=pe-ratio
Underlying data: Yahoo Finance; SEC EDGAR.